Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			10708315
Filing	iling Date		2004-02-24
First Named Inventor David		Davi	E. Mekas
Art Unit			1772
Examiner Name Alicia		Alicia	Ann Chevalier
Attorr	Attorney Docket Number		MASL-31

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Name of Patentee or Applicar of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6764621	B2	2004-0	7-20	Schwaighofer				
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines when ant Passages or Rele s Appear	
	1									
If you wish	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	or '	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	1
	1									
If you wish	h to a	dd additional Foreign F	atent Do	cument	citation	information pl	ease click the Add	button	Add	_
			NON	I-PATE	IT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initiats* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тs				

	Application Number		10708315	
INFORMATION DIGGS COURS	Filing Date		2004-02-24	
INFORMATION DISCLOSURE	First Named Inventor David		d E. Mekas	
(Not for submission under 37 CFR 1.99)	Art Unit		1772	
(Not lot bublingsion under or or it is say	Examiner Name	Alicia	cia Ann Chevalier	
	Attorney Docket Numb	er	MASL-31	

	1	Examiner Gregory A. Blankenship, Office Action, dated as being mailed July 27, 2006 in Application No. 10/904,010.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

EXAMINER SIGNATURE

Examiner Signature

Date Considered

Examiner Fignature

Date Considered

Examiner Fignature

Date Considered

Date Consid

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 99104. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the inclusion of the year of the religion of the Emperor must precede the serial number of the patent document. <sup>3</sup> Hond of document to the operation approach as an obtained not document under the Vision of the Vision of Standard ST.1 <sup>3</sup> For Standard ST.1 <sup>3</sup> For

English language translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708315
Filing Date		2004-02-24
First Named Inventor	David	E. Mekas
Art Unit		1772
Examiner Name	Alicia	Ann Chevalier
Attorney Docket Number		MASL-31

## CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) the statement of the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) and the statement of the

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David W. Dorton/	Date (YYYY-MM-DD)	2006-08-11					
Name/Print	David W. Dorton	Registration Number	51625					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.